MedTrace Logo

The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

NCT04829123 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2023-02-15

No results posted yet for this study

Summary

A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

DRUG

HEC88473 injection

HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen

DRUG

Placebo

Placebo will be administered by subcutaneous injection in the abdomen

Sponsors & Collaborators

  • Dongguan HEC Biopharmaceutical R&D Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Charlotte Lemech, Doctor · Scientia Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-14
Primary Completion
2022-03-02
Completion
2022-03-02

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04829123 on ClinicalTrials.gov